Literature DB >> 10735494

Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation.

A Claeskens1, N Ongenae, J M Neefs, P Cheyns, P Kaijen, M Cools, E Kutoh.   

Abstract

We have cloned a human Hevin cDNA from omental adipose tissue of different patients by reverse transcription polymerase chain reaction and shown a sequence variation due to a possible polymorphism at amino acid position 161 (E/G). Hevin protein expressed in vitro showed molecular weights of approximately 75 kDa and 150 kDa, suggesting that Hevin may form a homodimer in vitro. Using Northern blots and a human expressed sequence tAg database analysis, Hevin was shown to be widely expressed in human normal or non-neoplastic diseased tissues with various levels. In contrast to this, its expression was strongly down-regulated in most neoplastic cells or tissues tested. However, neither the mechanism nor the physiological meaning of this down-regulation is known. As an initial step towards investigating the functional role of Hevin in cell growth and differentiation, we transiently or stably expressed this gene in cancer cells (HeLa 3S) that are devoid of endogenous Hevin and measured DNA synthesis (cell proliferation) by 5-bromo-2'-deoxyuridine incorporation. Hevin was shown to be a negative regulator of cell proliferation. Furthermore, we have shown that Hevin can inhibit progression of cells from G1 to S phase or prolong G1 phase. This is the first report which describes the function of Hevin in cell growth and proliferation. Through database analysis, Hevin was found to be located on chromosome 4 which contains loss of heterozygosity of many tumour suppressor genes. Taken together, these results suggest that Hevin may be a candidate for a tumour suppressor gene and a potential target for cancer diagnosis/therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10735494      PMCID: PMC2363342          DOI: 10.1054/bjoc.1999.1051

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

1.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.

Authors:  M Gossen; H Bujard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

2.  Cloning from purified high endothelial venule cells of hevin, a close relative of the antiadhesive extracellular matrix protein SPARC.

Authors:  J P Girard; T A Springer
Journal:  Immunity       Date:  1995-01       Impact factor: 31.745

3.  Cooperation of Src homology domains in the regulated binding of phosphatidylinositol 3-kinase. A role for the Src homology 2 domain.

Authors:  B Haefner; R Baxter; V J Fincham; C P Downes; M C Frame
Journal:  J Biol Chem       Date:  1995-04-07       Impact factor: 5.157

4.  The Ca2(+)-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells.

Authors:  S E Funk; E H Sage
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

5.  Candidate gene analysis of GH1 for effects on growth and carcass composition of cattle.

Authors:  J F Taylor; L L Coutinho; K L Herring; D S Gallagher; R A Brenneman; N Burney; J O Sanders; J W Turner; S B Smith; R K Miller; J W Savell; S K Davis
Journal:  Anim Genet       Date:  1998-06       Impact factor: 3.169

6.  Functional interference between the ubiquitous and constitutive octamer transcription factor 1 (OTF-1) and the glucocorticoid receptor by direct protein-protein interaction involving the homeo subdomain of OTF-1.

Authors:  E Kutoh; P E Strömstedt; L Poellinger
Journal:  Mol Cell Biol       Date:  1992-11       Impact factor: 4.272

7.  Toxic effects of tacrine on primary hepatocytes and liver epithelial cells in culture.

Authors:  D Lagadic-Gossmann; M Rissel; M A Le Bot; A Guillouzo
Journal:  Cell Biol Toxicol       Date:  1998-10       Impact factor: 6.691

8.  A new candidate site for a tumor suppressor gene involved in mouse thymic lymphomagenesis is located on the distal part of chromosome 4.

Authors:  J Santos; M Herranz; I Pérez de Castro; A Pellicer; J Fernández-Piqueras
Journal:  Oncogene       Date:  1998-08-20       Impact factor: 9.867

9.  Long-term storage of samples for flow cytometric DNA analysis.

Authors:  L L Vindeløv; I J Christensen; N Keiding; M Spang-Thomsen; N I Nissen
Journal:  Cytometry       Date:  1983-03

10.  Transcriptional activation by tetracyclines in mammalian cells.

Authors:  M Gossen; S Freundlieb; G Bender; G Müller; W Hillen; H Bujard
Journal:  Science       Date:  1995-06-23       Impact factor: 47.728

View more
  25 in total

1.  Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.

Authors:  Paula J Hurley; Robert M Hughes; Brian W Simons; Jessie Huang; Rebecca M Miller; Brian Shinder; Michael C Haffner; David Esopi; Yasunori Kimura; Javaneh Jabbari; Ashley E Ross; Nicholas Erho; Ismael A Vergara; Sheila F Faraj; Elai Davicioni; George J Netto; Srinivasan Yegnasubramanian; Steven S An; Edward M Schaeffer
Journal:  Cancer Res       Date:  2015-08-20       Impact factor: 12.701

2.  SPARCL1: a potential molecule associated with tumor diagnosis, progression and prognosis of colorectal cancer.

Authors:  Hong Zhang; Emma Widegren; Da-Wei Wang; Xiao-Feng Sun
Journal:  Tumour Biol       Date:  2011-09-02

Review 3.  SIBLINGs and SPARC families: their emerging roles in pancreatic cancer.

Authors:  Ferda Kaleağasıoğlu; Martin R Berger
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

4.  Unique transcriptome, pathways, and networks in the human endometrial fibroblast response to progesterone in endometriosis.

Authors:  L Aghajanova; K Tatsumi; J A Horcajadas; A M Zamah; F J Esteban; C N Herndon; M Conti; L C Giudice
Journal:  Biol Reprod       Date:  2010-09-23       Impact factor: 4.285

5.  Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer.

Authors:  Irene Esposito; Hany Kayed; Shereen Keleg; Thomas Giese; E Helene Sage; Peter Schirmacher; Helmut Friess; Jörg Kleeff
Journal:  Neoplasia       Date:  2007-01       Impact factor: 5.715

6.  Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome.

Authors:  Paula J Hurley; Luigi Marchionni; Brian W Simons; Ashley E Ross; Sarah B Peskoe; Rebecca M Miller; Nicholas Erho; Ismael A Vergara; Mercedeh Ghadessi; Zhenhua Huang; Bora Gurel; Ben Ho Park; Elai Davicioni; Robert B Jenkins; Elizabeth A Platz; David M Berman; Edward M Schaeffer
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-27       Impact factor: 11.205

7.  Identification of genes differentially expressed in benign versus malignant thyroid tumors.

Authors:  Nijaguna B Prasad; Helina Somervell; Ralph P Tufano; Alan P B Dackiw; Michael R Marohn; Joseph A Califano; Yongchun Wang; William H Westra; Douglas P Clark; Christopher B Umbricht; Steven K Libutti; Martha A Zeiger
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

8.  Expression of SPARC like protein 1 (SPARCL1), extracellular matrix-associated protein is down regulated in gastric adenocarcinoma.

Authors:  Aniruddha Jakharia; Biswajyoti Borkakoty; Sujay Singh
Journal:  J Gastrointest Oncol       Date:  2016-04

9.  Microarray-based cancer prediction using soft computing approach.

Authors:  Xiaosheng Wang; Osamu Gotoh
Journal:  Cancer Inform       Date:  2009-05-26

10.  MIClique: An algorithm to identify differentially coexpressed disease gene subset from microarray data.

Authors:  Huanping Zhang; Xiaofeng Song; Huinan Wang; Xiaobai Zhang
Journal:  J Biomed Biotechnol       Date:  2010-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.